“Creating a vaccine against malaria has never been so close”

Je crois que c'etait Daniel S. qui avait fait un coup de gueule sur l'OMS et les labo. en donnant l'exemple d'une plante contre la malaria si je ne me trompe pas.

Voila qui devrait te faire plaisir.

A
candidate vaccine against malaria has recently undergone two promising
clinical studies. The first produced a 65% drop in the number of
infections and a 59% reduction in malaria attacks following infection.
The second, which focused on a particular adjuvant, also reduced the
number of episodes of malaria.
Developed by the GlaxoSmithKline (GSK)
laboratory, this vaccine was evaluated in the field in Tanzania and
Kenya. The first study involved 340 Tanzanian infants under the age of
one, who were monitored for 6 months. In addition to the positive
results already mentioned, it was also shown that the new candidate
vaccine does not compromise the effectiveness of other childhood
vaccines. This benefit appears to be certain, providing that all the
vaccines are administered at the same time.
The second study – involving 894 Kenyan and Tanzanian infants under the
age of 17 months – was aimed at evaluating the effectiveness and safety
of the vaccine in association with the new adjuvant ASO1. The verdict?
Malaria episodes dropped by 53% over an 8-month period. A better result
than was noted in a study conducted in Mozambique with another adjuvant
(ASO2) which only produced a 35% decrease over 18 months.
The director of the Malaria Vaccine Initiative, Christian Loucq, cannot
conceal his excitement. “Creating a vaccine against malaria has never
been so close”, he points out. For the MVI, an organisation funded by
the Bill and Melinda Gates Foundation, the next stage will be a phase
III study conducted in 7 African countries. And it will start as early
as 2009. This trial should be the last required before applying for
approval to market the vaccine.